How to buy Cogent Biosciences stock (COGT)

Cogent Biosciences is a biotechnology business based in the US. Cogent Biosciences shares (COGT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.84 – a decrease of 3.8% over the previous week. Cogent Biosciences employs 164 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Cogent Biosciences stock

Buy Cogent Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cogent Biosciences stock price (NASDAQ: COGT)

Use our graph to track the performance of COGT stocks over time.

Cogent Biosciences shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$7.84
52-week range	$4.28 - $12.61
50-day moving average more info button	$10.28
200-day moving average more info button	$8.94
Wall St. target price	$16.80
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.48

Is it a good time to buy Cogent Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cogent Biosciences price performance over time

Historical closes compared with the close of $7.8 from 2024-12-19

1 week (2024-12-13)	-4.29%
1 month (2024-11-21)	-13.14%
3 months (2024-09-20)	-28.96%
6 months (2024-06-21)	-11.26%

1 year (2023-12-21)	41.82%
2 years (2022-12-21)	-29.16%
3 years (2021-12-21)	8.46
5 years (2019-12-20)	186.76%

Cogent Biosciences financials

Gross profit TTM	$-121,627,000
Return on assets TTM	-44.02%
Return on equity TTM	-78.47%
Profit margin	0%
Book value	$1.85
Market Capitalization more info button	$843.9 million

TTM: trailing 12 months

Cogent Biosciences share dividends

We're not expecting Cogent Biosciences to pay a dividend over the next 12 months.

Have Cogent Biosciences's shares ever split?

Cogent Biosciences's shares were split on a 1:4 basis on 8 November 2020 . So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cogent Biosciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Cogent Biosciences shares which in turn could have impacted Cogent Biosciences's share price.

Cogent Biosciences share price volatility

Over the last 12 months, Cogent Biosciences's shares have ranged in value from as little as $4.28 up to $12.61. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cogent Biosciences's is 0.021. This would suggest that Cogent Biosciences's shares are less volatile than average (for this exchange).

Cogent Biosciences overview

Cogent Biosciences, Inc. , a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc.

Frequently asked questions

What percentage of Cogent Biosciences is owned by insiders or institutions?
Currently 0.124% of Cogent Biosciences shares are held by insiders and 111.156% by institutions. How many people work for Cogent Biosciences?
Latest data suggests 164 work at Cogent Biosciences. When does the fiscal year end for Cogent Biosciences?
Cogent Biosciences's fiscal year ends in December. Where is Cogent Biosciences based?
Cogent Biosciences's address is: 275 Wyman Street, Waltham, MA, United States, 02451 What is Cogent Biosciences's ISIN number?
Cogent Biosciences's international securities identification number is: US19240Q2012